1-Methyl-3-propyl-7-butylxanthine, a novel biochemical modulator, enhances therapeutic efficacy of adriamycin

Japanese Journal of Cancer Research

Volumn 89, Issue 2, 1998, Pages 228-234

  Sadzuka, Yasuyuki ^a   Iwazaki, Ayano ^a   Sugiyama, Tomomi ^a   Sawanishi, Takayuki ^b   Miyamoto, Ken Ichi ^c  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b HOKURIKU UNIVERSITY   (Japan)

^c KANAZAWA UNIVERSITY   (Japan)

Author keywords

1 Methyl 3 propyl 7 butylxanthine; Adriamycin; Biochemical modulation; Xanthine derivative

Indexed keywords

1 METHYL 3 PROPYLXANTHINE; ALKYL GROUP; DOXORUBICIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOCHEMISTRY; CONTROLLED STUDY; HEART; LIVER LEVEL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0031952418     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1998.tb00553.x     Document Type: Article

References (32)

1. Bertino, J. R., Sawicki, W. L., Lindquist, C. A. and Gupta, V. S. Schedule dependent antitumor effects of methotrexate and 5-fluorouracil. Cancer Res., 37, 327-328 (1977).
2. Budd, G. T., Fleming, R. M., Bukowski, R. M., McCracken, J. D., Rivkin, S. E., O'Bryan, R. M., Balcerzak, S. P. and MacDonald, J. S. 5-Fluorouracil and folinic acid in the treatment of advanced colorectal cancer. J. Clin. Oncol., 5, 272-277 (1987)
3. Hidalgo, O. F., Gonzalez, F., Gil, A., Camphell, W., Barrajon, E. and Lacave, A. J. 120 Hours simultaneous infusion of cisplatin and fluorouracil in metastatic breast cancer. Am. J. Clin. Oncol., 12, 397-401 (1989).
4. Iliakis, G., Nusse, M., Ganapathi, R., Egner, J. and Yen, A. Differential reduction by caffeine of adriamycin induced cell killing and cell delay in Chinese hamster V79 cells. Int. J. Rad. Oncol. Biol. Phys., 12, 1987-1995 (1986).
5. Shishir, K. D., Ching, C. L. and Arthur, B. P. Comparative analysis of caffeine and 3-aminobenzamide as DNA repair inhibitors in Syrian baby hamster kidney cells. Mutat. Res., 131, 71-79 (1984).
6. Tomita, K. and Tsuchiya, H. Enhancement of cytocidal and antitumor effect of cisplatin by caffeine in human osteosarcoma. Clin. Ther., 11, 43-52 (1989).
7. Tomita, K., Tsuchiya, H. and Sasaki, T. DNA repair and drug resistance : enhancement of the effects of anticancer agents by DKA repair inhibitors. Jpn. J. Cancer Chemother., 16, 576-584 (1989).
8. Tsuchiya, H., Tomita, K., Yasutake, H., Ueda, Y., Tanaka, M. and Sasaki, T. Growth inhibition and differentiation of murine melanoma B16-BL6 cells caused by the combination of cisplatin and caffeine. Jpn. J. Cancer Res., 80, 1246-1251 (1989).
9. Sadzuka, Y., Mochizuki, E. and Takino, Y. Caffeine modulates the antitumor activity and toxic side effects of adriamycin. Jpn. J. Cancer Res., 84, 348-353 (1993).
10. Sadzuka, Y., Mochizuki, E. and Takino, Y. Mechanism of caffeine modulation of the antitumor activity of adriamycin. Toxicol. Lett., 75, 39-49 (1995).
11. Sadzuka, Y., Mochizuki, E., Iwazaki, A., Hirota, S. and Takino, Y. Caffeine enhances adriamycin antitumor activity in Ehrlich ascites carcinoma-bearing mice. Biol. Pharm. Bull., 18, 159-161 (1995).
12. Sadzuka, Y., Iwazaki, A., Miyagishima, A., Nozawa, Y. and Hirota, S. Effects of methylxanthine derivatives on adriamycin concentration and antitumor activity. Jpn. J. Cancer. Res., 86, 594-599 (1995).
13. Sakai, R., Konno, K., Yamamoto, Y., Sanae, F., Takagi, K., Hasegawa, T., Iwasaki, N., Kakiuchi, M., Kato, H. and Miyamoto, K. Effects of alkyl substitutions of xanthine skeleton on bronchodilation. J. Med. Chem., 35, 4039-4044 (1992).
14. Tanizawa, H., Sazuka, Y. and Takino, Y. Micro-determination of lipoperoxide in the mouse myocardium by thiobarbituric acid fluorophotometry. Chem. Pharm. Bull., 29, 2910-2914 (1981).
15. Hafeman, D. G., Sunde, R. A. and Hoekstra, W. G. Effect of dietary selenium on erythrocyte and liver glutathione peroxidase in the rat. J. Nutr., 104, 580-587 (1974).
16. Beavo, J. A., Rogers, N. L., Crofford, O. B., Hardman, J. G., Sutherland, E. W. and Newman, E. V. Effects of xanthine derivatives on lipolysis and on adenosine 3′5′-monophosphate phosphodiesterase activity. Mol. Pharmacol., 6, 597-603 (1970).
17. Farrukh, I. S., Gurtner, G. H. and Michael, J. R. Pharmacological modification of pulmonary vascular injury: possible role of cAMP. J. Appl. Physiol., 62, 47-54 (1987).
18. Karlsson, J. A., Kjellin, G. and Persson, C. G. A. Effects on tracheal smooth muscle of adenosine and methylxanthines, and their interaction. J. Pharm. Pharmacol., 34, 788-793 (1982).
19. Murray, K. J. and England, P. J. Inhibitors of nucleotide phosphodiesterase as therapeutic agents. Biochem. Soc. Trans., 20, 460-464 (1992).
20. Miyamoto, K., Takagi, K., Sakai, R., Wakusawa, S., Koshiura, R., Nadai, M., Apichartpichean, R. and Hasegawa, T. Correlation between hydrophobicity of N-alkylxanthine derivatives and their biological activities on guinea-pig isolated tracheal smooth muscle. J. Pharm. Pharmacol., 41, 844-847 (1989).
21. Miyamoto, K., Sakai, R., Yamamoto, Y., Konno, K., Sanae, F., Hasegawa, T. and Takagi, K. Selective bronchodilators from 1-(5′-oxohexyl)xanthines. J. Pharm. Pharmacol., 44, 888-892 (1992).
22. Miyamoto, K., Yamamoto, Y., Kurita, M., Sakai, R., Konno, K., Sanae, F., Ohshima, T., Takagi, K., Hasegawa, T., Iwasaki, N., Kakiuchi, M. and Kato, H. Bronchodilator activity of xanthine derivatives substituted with functional groups at the 1- or 7-position. J. Med. Chem., 36, 1380-1386 (1993).
23. Miyamoto, K., Sakai, R., Kurita, M., Ohmae, S., Sanae, F., Sawanishi, H., Hasegawa, T. and Takagi, K. Effects of alkyl substituents of xanthine on phosphodiesterase isoenzymes. Biol. Pharm. Bull., 18, 431-434 (1995).
24. Takagi, K., Hasegawa, T., Kuzuya, T., Ogawa, K., Watanabe, T., Satake, T., Miyamoto, M., Wakusawa, S. and Koshiura, R. Structure-activity relationship in N3-alkylxanthine derivatives. Jpn. J. Pharmacol., 46, 373-378 (1988).
25. Sanae, F., Ohmae, S., Kurita, M., Sawanishi, H., Takagi, K. and Miyamoto, K. Structure-activity relationships of alkylxanthines: alkyl chain elongation at the N1 or N7-position decreases cardiotopic activity in the isolated guinea-pig heart. Jpn. J. Pharmacol., 69, 75-82 (1995).
26. Myers, C. E., Mcguire, W. P. and Young, R. C. Adriamycin: amelioration of toxicity by α-tocopherol. Cancer Treat. Rep., 60, 961-962 (1976).
27. Myers, C. E., Mcguire, W. P., Liss, R. H., Ifrim, I., Grotzinger, K. and Young, R. C. Adriamycin: the rule of lipid peroxidation in cardiac toxicity and tumor response. Science, 197, 165-167 (1977).
28. Sazuka, Y., Hirose, T., Hashimoto, J., Tanizawa, H. and Takino, Y. Species, strain, sex and weekly age differences of lipid peroxide levels in animal tissues before and after adriamycin administration. Chem. Pharm. Bull., 32, 4110-4116 (1984).
29. Sazuka, Y., Yoshikawa, K., Tanizawa, H. and Takino, Y. Effect of doxorubicin on lipid peroxide levels in tissues of mice. Jpn. J. Cancer Res., 78, 1280-1286 (1987).
30. Sazuka, Y., Tanizawa, H. and Takino, Y. Effect of adriamycin on the activities of Superoxide dismutase, glutathione peroxidase and catalase in tissues of mice. Jpn. J. Cancer Res., 80, 89-94 (1989).
31. Sazuka. Y., Tanizawa, H. and Takino, Y. Effect of adriamycin on DNA, RNA and protein biosynthesis in mouse tissues, in connection with its cardiotoxicity. Jpn. J. Cancer Res., 80, 1000-1005 (1989).
32. Tanizawa, H., Sazuka, Y. and Takino, Y. Change of lipid peroxide levels in mouse organs after adriamycin administration. Chem. Pharm. Bull., 31, 1714-1718 (1983).